Ivonescimab Shows Promising Results Over Pembrolizumab in NSCLC
Ivonescimab vs Pembrolizumab: A New Era in NSCLC Treatment
Recent findings presented at the 2024 World Conference on Lung Cancer reveal that ivonescimab offers a superior progression-free survival (PFS) rate compared to pembrolizumab for patients with non-small cell lung cancer (NSCLC). The phase 3 HARMONi-2 trial, led by Caicun Zhou, PhD, MD, involved a comparative study between these two therapies among patients with advanced NSCLC, showing a promising 5.3-month improvement in PFS.
Key Findings from HARMONi-2 Trial
- Ivonescimab: Demonstrated median PFS of 11.14 months.
- Pembrolizumab: Showed median PFS of 5.82 months.
- Overall response rate and disease control was higher with ivonescimab.
Discussion and Implications
The implications of these findings could shift the landscape of NSCLC treatment, as John Heymach, MD, PhD, reflects on whether we are witnessing a potential end to the established harmony in therapy choices. The safety profiles of both medications appeared comparable.
Research continues, and as noted by Zhou, this is the first phase 3 study indicating a marked efficacy change versus pembrolizumab in advanced NSCLC, potentially offering new hope for patients.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.